Cyclomydril (cyclopentolate hydrochloride and phenylephrine hydrochloride) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Cyclomydril - Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride solution/ Drops

    Get your patient on Cyclomydril - Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride solution/ Drops (Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride)

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Cyclomydril - Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride solution/ Drops prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    For the production of mydriasis.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    Instill one drop in each eye every five to ten minutes. To minimize systemic absorption, apply pressure over the nasolacrimal sac for two to three minutes following instillation. Observe infants closely for at least 30 minutes.

    Contraindications

    CONTRAINDICATIONS

    Do not use in patients with hypersensitivity to any component of this preparation.

    Adverse Reactions

    ADVERSE REACTIONS

    Ocular

    The following ocular adverse experiences have been associated with the use of CYCLOMYDRIL ® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution): increased intraocular pressure, burning/irritation upon instillation, photophobia, blurred vision and superficial punctate keratitis.

    Nonocular

    Use of cyclopentolate hydrochloride has been associated with psychotic reactions and behavioral disturbances in children. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place. This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common. Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include tachycardia, hyperpyrexia, hypertension, vasodilation, urinary retention, diminished gastrointestinal motility, convulsion, bradycardia, apnea, necrotizing colitis and abdominal distention (in newborns and especially premature infants), skin rash, drowsiness, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death. Systemic toxicity can result from topical application of sympathomimetic drugs: headache, blood pressure elevation, extrasystoles, tachycardia, syncope and cerebrovascular accidents have been reported.

    Description

    DESCRIPTION

    CYCLOMYDRIL ® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is a mydriatic prepared as a sterile topical ophthalmic solution. The active ingredients are represented by the chemical structures:

    Referenced Image

    Established Name:
    Cyclopentolate Hydrochloride

    Chemical Name:
    2-(Dimethylamino)ethyl 1 - hydroxy-α-phenylcyclopentaneacetate hydrochloride)

    Molecular Formula:
    C 17 H 25 NO 3 • HCl

    Molecular Weight:
    327.85 g/mol

    Referenced Image

    Established Name:
    Phenylephrine Hydrochloride

    Chemical Name:
    3-hydroxy-α[(methylamino)-methyl]-, Benzenemethanol, hydrochloride (R)-.

    Molecular Formula:
    C 9 H 13 NO 2 • HCl

    Molecular Weight:
    203.67 g/mol

    Each mL of CYCLOMYDRIL ® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) contains:
    Active: cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. Preservative: benzalkonium chloride 0.01%.
    Inactives: edetate disodium, boric acid, hydrochloric acid and /or sodium carbonate (to adjust pH), purified water.

    Pharmacology

    CLINICAL PHARMACOLOGY

    Cyclopentolate hydrochloride is an anticholinergic drug and phenylephrine hydrochloride is an adrenergic drug. This combination induces mydriasis that is greater than that of either drug alone at its respective concentration. The concentrations of cyclopentolate hydrochloride and phenylephrine hydrochloride have been selected to induce mydriasis with little accompanying cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    CYCLOMYDRIL ® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is supplied as a sterile solution in 2 mL and 5 mL, in plastic DROP-TAINER® dispensers.

    2 mL           NDC 0065-0359-02

    5 mL           NDC 0065-0359-05

    Storage: Store at 8°C to 25°C (46°F - 77°F)

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Cyclomydril - Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride solution/ Drops PubMed™ news

      Show the latest PubMed™ articles for Cyclomydril - Cyclopentolate Hydrochloride And Phenylephrine Hydrochloride solution/ Drops